Oncolytics announced a poster presentation made at the American Society of Hematology, or ASH. The poster highlights pelareorep’s ability to increase PD-L1 expression on tumor cells in patients with relapsed myeloma. This phase 1 study enrolled 15 patients with relapsed myeloma. Responses include: three very good partial responses, three partial remissions, three minimal responses and three stable disease. In patients receiving pelareorep with a clinical response, there was simultaneous CD8, PD-L1 and NK cell response, as well as activated caspase-3 expression. In patients treated with pelareorep, PD-L1 expression increased significantly more in patients with clinical response
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.